Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
详细信息 查看全文
- 作者：Kenneth H. Kima ; Danijela Jelovacb ; Deborah K. Armstrongb ; Benjamin Schwartzc ; Susan C. Weild ; Charles Schweizerd ; Ronald D. Alvareze ; ralvarez@uabmc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ovarian cancer ; Platinum-sensitive relapse ; Pegylated liposomal doxorubicin ; Farletuzumab ; Monoclonal antibody therapy
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：140
- 期：2
- 页码：210-214
- 全文大小：302 K
文摘
- •
Farletuzumab (FAR), a monoclonal antibody to folate receptor alpha, which is expressed in epithelial ovarian cancer (EOC).
- •
FAR has shown activity against EOC in platinum-sensitive relapse when combined with carboplatin and a taxane.
- •
Carboplatin in combination with pegylated liposomal doxorubicin (PLD) is a frequently used alterative regimen.
- •
This safety study assessed the addition of FAR to carboplatin/PLD, with a view toward future larger studies.
- •
This combination was generally well tolerated; adverse event profile was similar to that of carboplatin/PLD alone.